The US Federal Drug Administration (FDA) has received an orphan drug designation request from Vitality Biopharma Inc. (OTCQB: VBIO)—a cannabinoid prodrug pharma corporation in the process of developing its flagship asset VITA-100, targeting the treatment of pediatric ulcerative colitis. A positive … Read More
The post A New, Non-Corrosive, Non-Irritating Treatment for Pediatric Ulcerative Colitis Has Been Submitted … appeared first on Dagga Magazine.